Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of IV vs Oral LCB01-0371 in Healthy Male Volunteers
NCT02882789Phase 1Completed
- Sponsor
- LigaChem Biosciences
- Start
- Sep 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of delpazolid in bacterial infection and Tuberculosis (TB) (3 arms), sponsored by LigaChem Biosciences. Primary endpoints: Peak Plasma Concentration at 8 days and Safety and Tolerability at 8 days. Started Sep 2016; status: completed.
02
Drugs
delpazolid
03
Conditions
bacterial infectionTuberculosis (TB)
Beyond the preview
Go deeper on NCT02882789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02882789.